Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 8.9% – Time to Sell?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s share price traded down 8.9% during trading on Monday. The stock traded as low as $3.07 and last traded at $3.07. 88,257 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 118,054 shares. The stock had previously closed at $3.37.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Armata Pharmaceuticals in a research report on Tuesday, September 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Armata Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Armata Pharmaceuticals Trading Down 8.9%

The firm has a 50-day moving average of $4.43 and a 200-day moving average of $6.60. The stock has a market capitalization of $114.14 million, a price-to-earnings ratio of -0.40 and a beta of 1.40.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.17. The firm had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $0.40 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. On average, equities research analysts anticipate that Armata Pharmaceuticals, Inc. will post 0.50 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ARMP. Madison Asset Management LLC purchased a new position in Armata Pharmaceuticals in the first quarter valued at about $21,583,000. BlackRock Inc. bought a new stake in shares of Armata Pharmaceuticals during the 2nd quarter valued at about $3,629,000. Sei Investments Co. acquired a new stake in shares of Armata Pharmaceuticals during the 1st quarter worth approximately $760,000. Bank of New York Mellon Corp bought a new stake in Armata Pharmaceuticals in the second quarter valued at $193,000. Finally, Deutsche Bank AG acquired a new position in Armata Pharmaceuticals during the 2nd quarter worth $78,000. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat bacterial infections, including infections caused by antibiotic-resistant pathogens. Bacteriophages, or “phages,” are viruses that selectively target and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline includes investigational phage therapies for serious respiratory and systemic infections.